Citations

Clear

45 citation(s) found for "Grant, David".

Association of outpatient ACE inhibitors and angiotensin receptor blockers and outcomes of acute respiratory illness: a retrospective cohort study
Jeffery, Molly M. , Shah, Nilay D. , Bellolio, Fernanda , Jeffery, Molly Moore , Bellolio, M Fernanda , Cummins, Nathan W. , Dempsey, Timothy , Limper, Andrew H.

Mayo Clinic

BMJ Open | March 18, 2021 | Volume: 11 | Issue: 3 | Pages: e044010

10.1136/bmjopen-2020-044010 | PMID 33737435 Get It

Objectives Evaluate associations between ACE inhibitors (ACEis) and angiotensin receptor blockers (ARBs) and clinical outcomes in acute viral respiratory illness (AVRI). Design Retrospective cohort analysis of claims data. Setting The USA; 2018–2019 influenza season. Participants Main cohort: people with hypertension (HTN) taking an ACEi, ARB or other HTN medications, and experiencing AVRI. Falsification cohort: parallel cohort receiving elective knee or hip replacement. Main outcome measures Main cohort: hospital admission, intensive care unit, acute respiratory distress (ARD), ARD syndrome and all-cause mortality. Falsification cohort: complications after surgery and all-cause mortality. Results The main cohort included 236 843 episodes of AVRI contributed by 202 629 unique individuals. Most episodes were in women (58.9%), 81.4% in people with Medicare Advantage and 40.3% in people aged 75+ years. Odds of mortality were lower in the ACEi (0.78 (0.74 to 0.83)) and ARB (0.64 (0.61 to 0.68)) cohorts compared with other HTN medications. On all other outcomes, people taking ARBs (but not ACEis) had a >10% reduction in odds of inpatient stays compared with other HTN medications. In the falsification analysis (N=103 353), both ACEis (0.89 (0.80 to 0.98)) and ARBs (0.82 (0.74 to 0.91)) were associated with decreased odds of complications compared with other HTN medications; ARBs (0.64 (0.47 to 0.87)) but not ACEis (0.79 (0.60 to 1.05)) were associated with lower odds of death compared with other HTN medications. Conclusions Outpatient use of ARBs was associated with better outcomes with AVRI compared with other medications for HTN. ACEis were associated with reduced risk of death, but with minimal or no reduction in risk of other complications. A falsification analysis conducted to provide context on the possible causal implications of these findings did not provide a clear answer. Further analysis using observational data will benefit from additional approaches to assess causal relationships between these drugs and outcomes in AVRI.
Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis
Dempsey, Timothy , Payne, Stephanie , Sangaralingham, Lindsey R. , Shah, Nilay D. , Dempsey, Timothy M , Yao, Xiaoxi , Limper, Andrew H.

Mayo Clinic

Annals of the American Thoracic Society | January 19, 2021 | Volume: 18 | Issue: 7 | Pages: 1121-1128

10.1513/annalsats.202007-901oc | PMID 33465323 Get It

Abstract Rationale In October 2014, the antifibrotic medications pirfenidone and nintedanib became the first medications approved by the U.S. Food and Drug Administration for use in patients with idiopathic pulmonary fibrosis (IPF). Since approval, there has been no nonregistry analysis of the real-world adoption of these medications in everyday clinical practice. Objectives To evaluate the adoption, persistence, and out-of-pocket (OOP) costs of pirfenidone and nintedanib since their approval in the United States in 2014. Methods A retrospective cohort analysis was performed by identifying privately insured and Medicare Advantage beneficiaries with IPF. We then split the patients into three cohorts: those who were untreated and those who filled a prescription for either pirfenidone or nintedanib between October 1, 2014, and July 31, 2019. The primary outcome was adoption of the medications. Secondary outcomes included medication persistence and prescription drug costs. Results A total of 10,996 patients with IPF were identified in the data set. A minority of patients (26.4%) with IPF identified in the cohort had started either medication since approval in 2014, with the adoption of both medications being comparable at around 13.2%. Those receiving the medications were younger (72 vs. 73.9 yr; P < 0.0001) and healthier (3.9 vs. 4.9 comorbidities; P < 0.0001) than those not receiving treatment. Men were significantly more likely to receive treatment than woman (30.0% vs. 21.9%; P < 0.0001). Among treated patients, 42.8% discontinued the medications during the study period. Patients’ OOP expenses per month were high for both drugs (mean, $397.51 for nintedanib; mean, $394.49 for pirfenidone). Conclusions The adoption of both the antifibrotic medications in the United States in everyday practice has been low since approval and may be associated with the high OOP cost.
Anti-Fibrotic Therapy for Idiopathic Pulmonary Fibrosis Is Associated with Decreased Mortality Among Hospitalized Patients
Kelly, B., Thao, Viengneesee , Sangaralingham, Lindsey R. , Dempsey, Timothy , Payne, S., Limper, Andrew H.

Mayo Clinic

D105. ILD EPIDEMIOLOGY II | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A7798-A7798

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7798 Get It

Novel Research and Career Development Curriculum for Pulmonary and Critical Care Medicine Fellows
Pennington, Kelly M. , Ramar, K., Nelson, David , Dempsey, Timothy , Vassallo, R., Ramar, K., Nelson, D.

Mayo Clinic

A35. MEDICAL EDUCATION IN PULMONARY AND CRITICAL CARE MEDICINE | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A1433-A1433

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1433 Get It

Outcomes in single-level posterior cervical spine surgeries performed in the sitting and prone positions
Abcejo, Arnoley S., Kerezoudis, Panagiotis , Trelstad-Andrist, Katherine, Maloney, Patrick R. , Atkinson, John L. D., Meyer, Fredric B. , Marsh, W. Richard , Bydon, Mohamad , Bhargav, Adip G. , Himes, Benjamin

Mayo Clinic

Journal of Neurosurgery: Spine | July 3, 2020 | Volume: 33 | Issue: 5 | Pages: 667-673

10.3171/2020.4.spine191323 | PMID 32619981 Get It

OBJECTIVEThe sitting or semisitting position in neurosurgery allows for several technical advantages, including improved visualization of the surgical field. However, it has also been associated with an increased risk of venous air embolisms and positioning-related complications that limit its commonplace adoption. The authors report a large, single-center series of cervical spine procedures performed with patients in the sitting or prone position in order to assess the perceived risk of intraoperative and postoperative complications associated with the sitting position.METHODSNoninstrumented, single-level posterior cervical spine procedures performed with patients in the sitting/semisitting or prone position from 2000 to 2016 at a single institution were reviewed. Institutional abstraction tools (DataMart and Chart Plus) were used to collect data from the medical records. The two positions were compared with regard to preoperative factors, intraoperative variables, and postoperative outcomes. Multivariable logistic regression models were fitted for 30-day readmission, 30-day return to the operating room, and complication rates.RESULTSA total of 750 patients (sitting, n = 480; prone, n = 270) were analyzed. The median age was 53 years for those who underwent surgery in the prone position and 50 years for those who underwent surgery in the sitting position (IQRs 45–62 years and 43–60 years, respectively), and 35% of the patients were female. Sitting cases were associated with significantly longer anesthetic times (221 minutes [range 199–252 minutes] vs 205 minutes [range 179–254 minutes]) and operative times (126 minutes [range 101–163 minutes] vs 149 minutes [120–181 minutes]). Cardiorespiratory events in the postanesthesia care unit (PACU) were comparable between the two groups, with the exception of episodes of apnea (2.6% vs 0.6%, p = 0.041) and hypoventilation (4.4% vs 0.8%, p < 0.003), which were more frequent in the prone-position cohort. On multivariable analysis, the effect of the sitting versus the prone position was not significant for 30-day readmission (OR 0.77, 95% CI 0.34–1.71, p = 0.52) or reoperation (OR 0.71, 95% CI 0.31–1.60, p = 0.40). The sitting position was associated with lower odds of developing any complication (OR 0.31, 95% CI 0.16–0.62, p < 0.001).CONCLUSIONSBased on the intraoperative and postoperative complications chosen in this study, the sitting position confers a similar safety profile to the prone position. This can be explained by a more anatomic positioning accounting for reduced temporary neurological deficits and reduced PACU-associated hypoventilation noted in this series. Nevertheless, the findings may also reflect institutional familiarity, experience, and mastery of this position type, and outcomes may not reflect practices in general.
Miles to Go Before We Sleep. Reforming the Pulmonary and Critical Care Milestones to Improve Trainee Assessment
Heath, Janae K. , Santhosh, Lekshmi , Edgar, Laura , Fessler, H, Dempsey, Timothy M , Dempsey, Timothy

Mayo Clinic

ATS Scholar | March 3, 2020 | Volume: 1 | Issue: 1 | Pages: 33-43

10.34197/ats-scholar.2019-0013ps | PMID 33870267 Get It

Abstract The Accreditation Council for Graduate Medical Education (ACGME) Milestones are a systematic assessment framework for medical trainees within the six core competencies of practice. Their use by internal medicine subspecialties, including semiannual reports to the ACGME, was mandated beginning in 2014. The Milestones, which were based on specific, observable behaviors, improved upon the prior subjective, global comparisons of each fellow with an “average” fellow in his or her field and served the goals of competency-based medical education. However, the original set of Milestones has proven challenging to apply and interpret. Part of the challenge stems from the use of identical Milestones across all medicine subspecialties, which led to unclear relevance of the patient care and medical knowledge domains to the practice of pulmonary and critical care. This also precluded their use for individualized feedback or development of a learning plan for fellows. In addition, verbose behavioral descriptors, which were designed to provide specificity, ultimately led to rater fatigue among assessors and clinical competency committees. Therefore, the ACGME convened committees for each of the medical subspecialties to revise the original Milestones in an effort to improve subspecialty relevance, minimize educational jargon, and simplify the current iteration. New patient care and medical knowledge Milestones were created to be subspecialty specific and improve utility. The remaining four Milestones were developed as a common set of shorter Milestones, harmonized across specialties. For pulmonary, critical care, and combined fellowship programs, the resulting Milestones 2.0 aims to simplify the use, implementation, and interpretation of this framework for program directors, trainees, and society.
Mortality Effect of the Anti-Fibrotics Pirfenidone and Nintedanib in Clinical Practice
Sangaralingham, Lindsey R. , Yao, Xing-Sheng, Dempsey, Timothy , Limper, Andrew H.

Mayo Clinic

C35. HEALTH SERVICES RESEARCH IN COUGH, CF, AND ILD | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A7393-A7393

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7393 Get It

Pulmonary Mastocytosis Manifesting as Chronic Cough
Dempsey, Timothy , Vassallo, Robert

Mayo Clinic

D41. COUGH AND IMMUNODEFICIENCIES CASE REPORTS | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A6381-A6381

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6381 Get It

Adoption of the Anti-Fibrotic Medications Pirfenidone and Nintedanib Among Commercially-Insured Adults in the United States
Sangaralingham, Lindsey R. , Dempsey, Timothy , Yao, Xiaoxi , Limper, Andrew H.

Mayo Clinic

D22. REAL WORLD MEDICATION USE IN PULMONARY DISEASES | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5920-A5920

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5920 Get It

Reply to Callahan: Identifying “Real” Patients in the Real World
Dempsey, Timothy , Limper, Andrew H. , Dempsey, Timothy M

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 16, 2019 | Volume: 201 | Issue: 2 | Pages: 257-258

10.1164/rccm.201908-1538le | PMID 31419393 Get It